1. Midkine as a driver of age-related changes and increase in mammary tumorigenesis.
- Author
-
Yan P, Jimenez ER, Li Z, Bui T, Seehawer M, Nishida J, Foidart P, Stevens LE, Xie Y, Gomez MM, Park SY, Long HW, and Polyak K
- Subjects
- Animals, Female, Humans, Rats, Carcinogenesis genetics, Mammary Glands, Animal pathology, Mammary Glands, Animal metabolism, Cell Proliferation, Mammary Neoplasms, Experimental pathology, Mammary Neoplasms, Experimental genetics, Mammary Neoplasms, Experimental chemically induced, Mammary Neoplasms, Experimental metabolism, Cell Transformation, Neoplastic genetics, Cell Transformation, Neoplastic metabolism, Cell Transformation, Neoplastic pathology, Signal Transduction, Methylnitrosourea toxicity, Midkine metabolism, Midkine genetics, Breast Neoplasms pathology, Breast Neoplasms metabolism, Breast Neoplasms etiology, Breast Neoplasms genetics, Aging pathology
- Abstract
Aging is a pivotal risk factor for cancer, yet the underlying mechanisms remain poorly defined. Here, we explore age-related changes in the rat mammary gland by single-cell multiomics. Our findings include increased epithelial proliferation, loss of luminal identity, and decreased naive B and T cells with age. We discover a luminal progenitor population unique to old rats with profiles reflecting precancerous changes and identify midkine (Mdk) as a gene upregulated with age and a regulator of age-related luminal progenitors. Midkine treatment of young rats mimics age-related changes via activating PI3K-AKT-SREBF1 pathway and promotes nitroso-N-methylurea-induced mammary tumorigenesis. Midkine levels increase with age in human blood and mammary epithelium, and higher MDK in normal breast tissue is associated with higher breast cancer risk in younger women. Our findings reveal a link between aging and susceptibility to tumor initiation and identify midkine as a mediator of age-dependent increase in breast tumorigenesis., Competing Interests: Declaration of interests K.P. serves on the Scientific Advisory Board of Ideaya Biosciences and Scorpion Therapeutics, holds equity options in Scorpion Therapeutics and Ideaya Biosciences, and receives sponsored research funding from Novartis where she also consults. L.E.S. is current employee of Astra-Zeneca. H.W.L. receives research funding from Novartis., (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF